Change of Control Agreements in the Biotechnology Industry

491 Contracts & Agreements

Browse by Company

4D Molecular Therapeutics Inc (7 contracts)
AbbVie Inc. (1)
ACADIA PHARMACEUTICALS INC (3)
Achaogen, Inc. (4)
ACHIEVE LIFE SCIENCES, INC. (1)
Advaxis, Inc. (1)
Adverum Biotechnologies, Inc. (20)
AGENUS INC (3)
ALBIREO PHARMA, INC. (2)
Aldeyra Therapeutics, Inc. (2)
Alector, Inc. (1)
Aligos Therapeutics, Inc. (1)
Allakos Inc. (1)
Allogene Therapeutics, Inc. (1)
ALNYLAM PHARMACEUTICALS, INC. (2)
ALPINE IMMUNE SCIENCES, INC. (2)
ALX ONCOLOGY HOLDINGS INC (1)
AMARIN CORP PLC (1)
Amgen Inc. (6)
AMICUS THERAPEUTICS, INC. (16)
AmpliPhi Biosciences Corp (1)
Anika Therapeutics (1)
Applied Molecular Transport Inc. (2)
Aravive, Inc. (1)
ARCA biopharma, Inc. (1)
Arcellx, Inc. (2)
Arcus Biosciences, Inc. (2)
Arcutis Biotherapeutics, Inc. (11)
ARDELYX, INC. (15)
aTYR PHARMA INC (1)
AVEO PHARMACEUTICALS INC (17)
BioAtla, Inc. (1)
BioCardia, Inc. (1)
Biomea Fusion, Inc. (2)
BIOSPECIFICS TECHNOLOGIES CORP (6)
Blueprint Medicines Corp (1)
Bolt Biotherapeutics, Inc. (1)
CareDx, Inc. (2)
CASI Pharmaceuticals, Inc. (2)
CASTLE BIOSCIENCES INC (1)
CATALYST PHARMACEUTICALS, INC. (1)
Celsion CORP (9)
CM Life Sciences III Inc. (1)
Coherus BioSciences, Inc. (1)
Constellation Alpha Capital Corp. (2)
CONSTELLATION PHARMACEUTICALS INC (1)
Cortexyme, Inc. (12)
Corvus Pharmaceuticals, Inc. (3)
Cyclacel Pharmaceuticals, Inc. (1)
CytomX Therapeutics, Inc. (11)
Day One Biopharmaceuticals Holding Co LLC (1)
Decibel Therapeutics, Inc. (3)
Denali Therapeutics Inc. (1)
Dermira, Inc. (1)
Dynamics Special Purpose Corp. (3)
Dyne Therapeutics, Inc. (2)
Edge Therapeutics, Inc. (1)
Emerald Bioscience, Inc. (1)
Epizyme, Inc. (4)
Erasca, Inc. (1)
Exelixis (7)
FATE THERAPEUTICS INC (1)
FIBROGEN INC (3)
Forty Seven, Inc. (1)
Gene Biotherapeutics, Inc. (3)
Global Blood Therapeutics, Inc. (7)
HALOZYME THERAPEUTICS INC (5)
HERON THERAPEUTICS, INC. (1)
IDERA PHARMACEUTICALS, INC. (3)
IGM Biosciences, Inc. (2)
Imago BioSciences, Inc. (1)
IMMUNOGEN INC (28)
INFINITY PHARMACEUTICALS, INC. (1)
Invitae Corp (3)
IRONWOOD PHARMACEUTICALS INC (2)
Janux Therapeutics, Inc. (1)
Kiniksa Pharmaceuticals, Ltd. (1)
Kinnate Biopharma Inc. (5)
Kronos Bio, Inc. (2)
Ligand Pharmaceuticals Incorporated (1)
MADRIGAL PHARMACEUTICALS, INC. (7)
MeiraGTx Holdings plc (1)
MiMedx Group, Inc. (3)
MiNK Therapeutics, Inc. (1)
Molecular Templates, Inc. (13)
Morphic Holding, Inc. (5)
Myriad Genetics, Inc. (2)
NOVAVAX INC (2)
Nurix Therapeutics, Inc. (2)
OncoCyte Corp (4)
ONCOSEC MEDICAL Inc (1)
OPGEN INC (10)
Organogenesis Holdings Inc. (3)
ORGANOVO HOLDINGS, INC. (3)
Oric Pharmaceuticals, Inc. (1)
Oyster Point Pharma, Inc. (1)
PhaseBio Pharmaceuticals Inc (1)
PMV Pharmaceuticals, Inc. (7)
PORTOLA PHARMACEUTICALS INC (1)
Poseida Therapeutics, Inc. (1)
Principia Biopharma Inc. (2)
RECURSION PHARMACEUTICALS, INC. (2)
Regeneron Pharmaceuticals (2)
REGENERX BIOPHARMACEUTICALS INC (9)
RenovoRx, Inc. (4)
RIGEL PHARMACEUTICALS INC (3)
RITTER PHARMACEUTICALS INC (6)
ROCKET PHARMACEUTICALS, INC. (2)
Sage Therapeutics, Inc. (8)
Sana Biotechnology, Inc. (1)
Sarepta Therapeutics, Inc. (5)
Savara Inc (1)
SELLAS Life Sciences Group, Inc. (1)
Sigilon Therapeutics, Inc. (1)
Silverback Therapeutics, Inc. (1)
Sorrento Therapeutics, Inc. (1)
Spectrum Pharmaceuticals, Inc. (3)
SPRUCE BIOSCIENCES, INC. (2)
Stoke Therapeutics, Inc. (4)
SUNESIS PHARMACEUTICALS INC (1)
SUTRO BIOPHARMA, INC. (3)
SYNLOGIC, INC. (1)
T2 Biosystems, Inc. (9)
Talaris Therapeutics, Inc. (1)
Taysha Gene Therapies, Inc. (1)
Tenaya Therapeutics, Inc. (2)
Tocagen Inc (1)
United Therapeutics Corp (3)
Vaxart, Inc. (3)
Vaxcyte, Inc. (1)
VERACYTE, INC. (20)
Vertex Pharmaceuticals Inc (6)
Vir Biotechnology, Inc. (1)
VITAL THERAPIES INC (2)
Vor Biopharma Inc. (1)
Xencor Inc (1)
XOMA Corp (10)
ZAFGEN, INC. (12)

Recent Contracts

Updated Form Executive Change in Control and Severance Agreement adopted November 13, 2023 (Biomea Fusion, Inc., Filed With SEC on March 28, 2024)
Severance and Change in Control Plan of the Company (SUTRO BIOPHARMA, INC., Filed With SEC on March 25, 2024)
Change in Control Severance Plan and Summary Plan Description (Sana Biotechnology, Inc., Filed With SEC on February 29, 2024)
Amended and Restated Change in Control and Severance Agreement, dated June 23, 2023 by and between Robert Kim and the Registrant (4D Molecular Therapeutics Inc, Filed With SEC on February 29, 2024)
Change in Control and Severance Agreement, dated September 22, 2021, by and between Scott Bizily and the Registrant (4D Molecular Therapeutics Inc, Filed With SEC on February 29, 2024)
Change in Control and Severance Agreement, dated August 29, 2023, by and between Uneek Mehra and the Registrant (4D Molecular Therapeutics Inc, Filed With SEC on February 29, 2024)
Change of Control and Severance Agreement, effective (VERACYTE, INC., Filed With SEC on February 29, 2024)
Change of Control and Severance Agreement, effective September 1, 2023, between John Leite and the Registrant (VERACYTE, INC., Filed With SEC on February 29, 2024)
Severance and Change of Control Agreement, dated December 11, 2023, by and between Myriad Genetics, Inc. and Samraat S. Raha (Myriad Genetics, Inc., Filed With SEC on February 28, 2024)
Castle Biosciences, Inc. Severance and Change in Control Plan (CASTLE BIOSCIENCES INC, Filed With SEC on February 28, 2024)
Severance and Change in Control Plan (CATALYST PHARMACEUTICALS, INC., Filed With SEC on February 28, 2024)
Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated (Exelixis, Filed With SEC on February 6, 2024)
Alpine Immune Sciences, Inc. Change of Control and Severance Policy, as amended and restated effective January 4, 2024 (ALPINE IMMUNE SCIENCES, INC., Filed With SEC on January 5, 2024)
Executive Change in Control and Severance Agreement between Quince Therapeutics, Inc. and Charles Ryan, dated as of September 1, 2023 (Cortexyme, Inc., Filed With SEC on November 14, 2023)
Change in Control Severance Agreement dated as of September18, 2023 between the Registrant and Lauren White (IMMUNOGEN INC, Filed With SEC on November 2, 2023)
Form of Amendment to Change of Control and Severance Agreement, dated June 1, 2023 (RenovoRx, Inc., Filed With SEC on August 16, 2023)
Form of Change in Control and Severance Agreement for executive officers other than the chief executive officer (Adverum Biotechnologies, Inc., Filed With SEC on August 10, 2023)
Severance and Change in Control Policy, effective as of February 14, 2023 (ROCKET PHARMACEUTICALS, INC., Filed With SEC on August 9, 2023)
EQRx, Inc. Amended and Restated Severance and Change of Control Policy (CM Life Sciences III Inc., Filed With SEC on August 8, 2023)
Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and each of its executive officers other than Sean A. McCarthy (CytomX Therapeutics, Inc., Filed With SEC on August 8, 2023)
IGM Biosciences, Inc. Amended and Restated Change in Control and Severance Policy (IGM Biosciences, Inc., Filed With SEC on August 3, 2023)
Exelixis, Inc. Change in Control and Severance Benefit Plan, as amended and restated (Exelixis, Filed With SEC on August 1, 2023)
Senior Executive Change in Control and Severance Policy, as amended, and forms of agreement thereunder (Applied Molecular Transport Inc., Filed With SEC on July 24, 2023)
Executive Change in Control and Severance Plan, as amended (Tenaya Therapeutics, Inc., Filed With SEC on June 12, 2023)
Form of Change in Control Severance Agreement (Ligand Pharmaceuticals Incorporated, Filed With SEC on May 8, 2023)
Executive Change in Control and Severance Plan, effective January 1, 2023 (Coherus BioSciences, Inc., Filed With SEC on May 8, 2023)
Change in Control Severance Agreement dated as of December 29, 2022 between the Registrant and Michael J. Vasconcelles (IMMUNOGEN INC, Filed With SEC on March 1, 2023)
Change in Control Severance Agreement dated as of January 5, 2021 between the Registrant and Renee Lentini (IMMUNOGEN INC, Filed With SEC on March 1, 2023)
Change of Control and Severance Agreement, effective January 1, 2023, between Annie McGuire and the Registrant (VERACYTE, INC., Filed With SEC on March 1, 2023)
Amended & Restated Change in Control and Executive Severance Plan Agreement, by and between the Company and Joshua Riggs, effective as of December 2, 2022 (OncoCyte Corp, Filed With SEC on December 5, 2022)
Form of Change in Control and Severance Agreement (Tocagen Inc, Filed With SEC on November 14, 2022)
Severance and Change in Control Agreement between the Company and Tim Lu (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Severance and Change in Control Agreement between the Company and Philip Lee (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Severance and Change in Control Agreement between the Company and Deborah Knobelman (Dynamics Special Purpose Corp., Filed With SEC on November 10, 2022)
Change of Control and Severance Agreement, dated July 18, 2022 by and between Invitae Corporation and Kenneth D. Knight (Invitae Corp, Filed With SEC on November 8, 2022)
Amended and Restated Executive Severance and Change in Control Benefits Plan (Dyne Therapeutics, Inc., Filed With SEC on November 3, 2022)
Form of Agreement Regarding Change in Control by and between AbbVie Inc. and its named executive officers (AbbVie Inc., Filed With SEC on October 14, 2022)
BioAtla, Inc. Management Change of Control Severance Plan (BioAtla, Inc., Filed With SEC on September 21, 2022)
Change in Control and Severance Agreement by and between RenovoRx, Inc. and Angela Gill Nelms, dated August 17, 2022 (RenovoRx, Inc., Filed With SEC on September 19, 2022)
Executive Change in Control and Severance Agreement, by and between Cortexyme, Inc. and Dirk Thye, dated as of May 19, 2022 (Cortexyme, Inc., Filed With SEC on August 9, 2022)